Navigation Links
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
Date:2/25/2013

biomanufacturing, the net result being high quality products with low cost of goods.  Together we are well positioned to provide emerging countries access to affordable, high-quality biopharmaceutical products for critical indications."

Oncobiologics Founder and CEO, Pankaj Mohan , Ph.D., added, "We are thrilled to have Viropro as an anchor partner. Together we form a fully integrated biopharmaceutical alliance to serve the emerging markets.  The combination of a state-of-the-art biologics manufacturing facility and support from the Malaysian Government makes Viropro an ideal partner. This unique partnership allows us to bring together technical expertise and quality oversight from the U.S. with a high capability, low cost biologics operation in Malaysia."

Dato' Dr. Mohd Nazlee Kamal , CEO of Malaysian BiotechCorp, commented, "Malaysia's strategy to become a biotech hub for Asia is rapidly gaining traction, and this Viropro/ Oncobiologics partnership is a significant step in moving this effort forward. BiotechCorp is proud to be part of this collaboration and we look forward to many great developments. This project will attract interest in the biosimilars manufacturing field and will certainly build the confidence of global biotech companies in Malaysian companies as we strive to develop the biomedical sector in the country."  Malaysian BiotechCorp is an agency under the Ministry of Science, Technology and Innovation (MOSTI) responsible for executing the objectives of the National Biotechnology Policy (NBP).

Proximare, a strategic advisory firm focused on the life sciences and healthcare industries, acted as advisor for the deal.   Financial terms were not disclosed.

About Oncobiologics, Inc.

Oncobiologics is a privately-held biopharmaceutical company developing a pipeli
'/>"/>

SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
2. Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board
3. Research and Markets: Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome
4. New Product Launch: Are your Strategies for Emerging Healthcare and Life Sciences Markets Innovative and Structured?
5. Webinar to Discuss Biosimilar Regulatory Guidelines in India and Emerging Markets
6. Intellitech Announces New Micro Pump Promotes Rapid Growth of Emerging BioTech
7. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
8. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
9. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
10. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2013)... This training is ideal for those who will be ... industry or those who want to explore Agile and Scrum, ... topics that will be covered in the 1-day Agile and ... artifacts, and scrum simulation (optional). , The trainings will ... 28, 2013 , Click here to register for a class. ...
(Date:6/14/2013)... These couplings are LinkTech’s smallest connectors ... a new and improved “Easy Grip Barrel” that provides ... and reliable connection every time. , The LinkTech interchangeable ... medical applications such as blood pressure cuffs. ... with better, more reliable, high quality, and cost effective ...
(Date:6/14/2013)... (PRWEB) June 14, 2013 Rosacea is said ... acne affects nearly 17 million; combined, it seems that most ... conditions mentioned. As U.S. News reports, often deciphering ... difficult as they all seem to have similar symptoms. Probiotic ... advice on how to treat them effectively. , Rosacea, Acne ...
(Date:6/14/2013)... , June 14, 2013  The Pittsburgh Life ... and levels of investment that were necessitated by delays ... overall investment climate and the uncertainty of state funding. ... said, "As the region,s only pure life sciences ... approved by the PLSG Board of Directors, were necessary ...
Breaking Biology Technology:Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2LinkTech Inc. Launches Ideal Replacement for a Luer Fitting 2LinkTech Inc. Launches Ideal Replacement for a Luer Fitting 3Rosacea, Acne, or Eczema? Probiotic Action Offers a Topical Probiotic to Treat the Most Common Skin Conditions 2Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding 2
... adds new line of heart disease and diabetes ... 20 Atherotech, Inc. ... Cholesterol Test in booth #912 at Internal Medicine ... College of Physicians (ACP). The conference takes place ...
... Proof of Mechanism of a Potential Oral Antagonist for ... Amira Pharmaceuticals, Inc., announced today the initiation of ... discovered oral drug candidate for the treatment and control ... acid pathway.AM211 is an oral, selective antagonist of the ...
... Data are New Releases for the Company Building ... Discoveries --DENVER, April 20 DXL625 ... antibodies in their ability to attach and deplete ... research conducted at InNexus Biotechnology Inc. (Toronto Stock ...
Cached Biology Technology:Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 2Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 3Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 3
(Date:6/14/2013)... the only ones tending their gardens. , At the ... ants cultivate thriving communities of fungi and bacteria using ... are a source of food and shelter for the ... biofuel production. , "We are interested in the whole ... goes in and is converted to energy for the ...
(Date:6/14/2013)... By identifying a protein that acts as a ... have solved the mystery of why some infants are ... and major deformities of the skin and limbs, while ... little or no sign of the illness, called EEC. ... It is rare in its full-blown form, although individual ...
(Date:6/14/2013)... Data presented at EULAR 2013, the Annual Congress of ... biomarkers could significantly improve diagnosis in rheumatoid arthritis (RA). ... and UH-RA.21 were investigated; as a group they ... both early and seronegative disease, with 36% of ... patients testing positive. , RA is a chronic ...
Breaking Biology News(10 mins):Researchers unearth bioenergy potential in leaf-cutter ant communities 2Researchers unearth bioenergy potential in leaf-cutter ant communities 3CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 2CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 3
... The best place to enjoy a breath of fresh air may ... A team of graduating seniors has created a system for public ... lead to tuberculosis (TB), flu and pneumonia. The CityBusters ... Chen, all seniors have installed a $500 device on a ...
... significantly slow the pace of climate change with practical ... bringing successful Western technologies to the developing world, according ... Foreign Affairs . For the last two ... to make progress. Part of the problem, the ...
... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... its first quarter ended March 31, 2012.  Revenues ... of 10% compared to $6.4 million in the same quarter last ... million, or $0.05 per diluted share. These results compared to net ...
Cached Biology News:College students work to sterilize air, kill pathogens on buses 2College students work to sterilize air, kill pathogens on buses 3College students work to sterilize air, kill pathogens on buses 4UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 2UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 3UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 4Aware, Inc. Reports First Quarter 2012 Financial Results 2Aware, Inc. Reports First Quarter 2012 Financial Results 3Aware, Inc. Reports First Quarter 2012 Financial Results 4Aware, Inc. Reports First Quarter 2012 Financial Results 5
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
Biology Products: